Shares of drugmaker Teva (NYSE:TEVA) stumbled in 2013, finishing the year far behind the S&P 500.

TEVA Total Return Price Chart

TEVA Total Return Price data by YCharts

Today, however, this stock trades at an attractive multiple and could be set for a rebound in 2014. But is it smooth sailing ahead for this unique drugmaker, or are there challenges in the coming years that should worry investors? Analyst Max Macaluso explores this stock in the following video and presents one reason to avoid Teva and one reason to be optimistic about the stock's future.

Editor's Note: At 2:37, Max meant to say Teva appointed "Erez Vigodman."

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.